## Melanie J Davies

## List of Publications by Citations

Source: https://exaly.com/author-pdf/12116852/melanie-j-davies-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 7,865 66 27 h-index g-index citations papers 66 6.26 9,798 11.4 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
62	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , <b>2018</b> , 41, 2669-2701	14.6	1307
61	Type 2 diabetes. <i>Lancet, The</i> , <b>2017</b> , 389, 2239-2251	40	935
60	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , <b>2018</b> , 61, 2461-2498	10.3	656
59	Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1716-30	59.2	574
58	Three-year efficacy of complex insulin regimens in type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1736-47	59.2	522
57	Effect of valsartan on the incidence of diabetes and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 1477-90	59.2	493
56	Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 687-99	27.4	468
55	Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. <i>Diabetes Care</i> , <b>2013</b> , 36, 3411-7	14.6	416
54	Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. <i>Diabetes Care</i> , <b>2014</b> , 37, 922-33	14.6	357
53	Association of sedentary behaviour with metabolic syndrome: a meta-analysis. <i>PLoS ONE</i> , <b>2012</b> , 7, e349	<b>16</b> 7	307
52	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. <i>BMJ, The</i> , <b>2012</b> , 344, e2333	5.9	214
51	Considerations when using the activPAL monitor in field-based research with adult populations. Journal of Sport and Health Science, <b>2017</b> , 6, 162-178	8.2	209
50	Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1915-1924	6.7	173
49	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. <i>Diabetes Care</i> , <b>2016</b> , 39, 130-8	14.6	171
48	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , <b>2014</b> , 383, 1059-66	40	143
47	Sedentary time and markers of chronic low-grade inflammation in a high risk population. <i>PLoS ONE</i> , <b>2013</b> , 8, e78350	3.7	109
46	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet, The</i> , <b>2021</b> , 396, 2019-2082	40	90

## (2019-2017)

45	Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1024-1031	6.7	79
44	Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2016</b> , 164, 102-13	8	60
43	Sedentary behaviour as a new behavioural target in the prevention and treatment of type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2016</b> , 32 Suppl 1, 213-20	7.5	55
42	Accuracy of Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. <i>Medicine and Science in Sports and Exercise</i> , <b>2016</b> , 48, 1085-90	1.2	54
41	A Randomised Controlled Trial to Reduce Sedentary Time in Young Adults at Risk of Type 2 Diabetes Mellitus: Project STAND (Sedentary Time ANd Diabetes). <i>PLoS ONE</i> , <b>2015</b> , 10, e0143398	3.7	47
40	Stand More AT Work (SMArT Work): using the behaviour change wheel to develop an intervention to reduce sitting time in the workplace. <i>BMC Public Health</i> , <b>2018</b> , 18, 319	4.1	42
39	Associations Between Sedentary Behaviors and Cognitive Function: Cross-Sectional and Prospective Findings From the UK Biobank. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 441-454	3.8	31
38	Associations of reallocating sitting time into standing or stepping with glucose, insulin and insulin sensitivity: a cross-sectional analysis of adults at risk of type 2 diabetes. <i>BMJ Open</i> , <b>2017</b> , 7, e014267	3	27
37	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 554-61	12.7	27
36	Fitness Moderates Glycemic Responses to Sitting and Light Activity Breaks. <i>Medicine and Science in Sports and Exercise</i> , <b>2017</b> , 49, 2216-2222	1.2	23
35	Associations of Sedentary Time with Fat Distribution in a High-Risk Population. <i>Medicine and Science in Sports and Exercise</i> , <b>2015</b> , 47, 1727-34	1.2	21
34	Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese high-risk adults: A randomized crossover trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1732-1739	6.7	17
33	Clinical inertia versus overtreatment in glycaemic management. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2018</b> , 6, 266-268	18.1	17
32	Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135702	3.7	17
31	PRomotion Of Physical activity through structured Education with differing Levels of ongoing Support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 289	2.8	16
30	The right place for Sulphonylureas today. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 157, 107836	7.4	14
29	Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. <i>Drugs</i> , <b>2019</b> , 79, 173-186	12.1	13
28	Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1967-1972	6.7	11

27	A three arm cluster randomised controlled trial to test the effectiveness and cost-effectiveness of the SMART Work & Life intervention for reducing daily sitting time in office workers: study protocol. <i>BMC Public Health</i> , <b>2018</b> , 18, 1120	4.1	11
26	Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation. <i>Journal of Sports Sciences</i> , <b>2018</b> , 36, 1586-1593	3.6	9
25	Change in Sedentary Time, Physical Activity, Bodyweight, and HbA1c in High-Risk Adults. <i>Medicine and Science in Sports and Exercise</i> , <b>2017</b> , 49, 1120-1125	1.2	8
24	A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1187-1196	6.7	7
23	Self-Compassion, Metabolic Control and Health Status in Individuals with Type 2 Diabetes: A UK Observational Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2021</b> , 129, 413-419	2.3	7
22	New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2016</b> , 4, 557-9	18.1	6
21	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , <b>2015</b> , 5, e007901	3	6
20	A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1101-1110	6.7	5
19	Optimizing management of glycaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 30, 397-411	6.5	5
18	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. <i>Programme Grants for Applied Research</i> , <b>2017</b> , 5, 1-290	1.5	5
17	Movement through Active Personalised engagement (MAP) - a self-management programme designed to promote physical activity in people with multimorbidity: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2018</b> , 19, 576	2.8	5
16	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 1164-1168	3.2	4
15	Type 2 diabetes - Authors Leply. Lancet, The, <b>2018</b> , 391, 1262	40	3
14	Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 218-227	6.7	3
13	Type 2 diabetes: lifetime risk of advancing from prediabetes. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2016</b> , 4, 5-6	18.1	2
12	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e034137	3	1
11	Energy intake and weight during the COVID-19 lockdown were not altered in a sample of older adults with type 2 diabetes in England. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> ,	6.7	1
10	The General Practitioner Prompt Study to Reduce Cardiovascular and Renal Complications in Patients With Type 2 Diabetes and Renal Complications: Protocol and Baseline Characteristics for a Cluster Randomized Controlled Trial. <i>JMIR Research Protocols</i> , <b>2018</b> , 7, e152	2	1

## LIST OF PUBLICATIONS

9	PROPELS randomised controlled trial. <i>BMC Medicine</i> , <b>2021</b> , 19, 130	11.4 1	
8	Handbook of Insulin Therapies <b>2016</b> ,	1	
7	Ethnic, social and multimorbidity disparities in therapeutic inertia: A UK primary care observational study in patients newly diagnosed with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2	43 <del>7-</del> 2445 <sup>1</sup>	
6	Response to comment on Khunti et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes care 2013;36:3411-3417. <i>Diabetes Care</i> , <b>2014</b> , 37, e114	14.6 0	
5	Prevention of type 2 diabetes <b>2015</b> , 550-563		
4	Sedentary Behaviour, Diabetes, and the Metabolic Syndrome. <i>Springer Series on Epidemiology and Public Health</i> , <b>2018</b> , 193-214	0.4	
3	Practical Aspects of Insulin Therapy <b>2016</b> , 169-209		
2	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 132, 137-143	7.4	

Insulin Management in Type 2 Diabetes **2016**, 83-131